In push to ex­pand its CAR-T ther­a­pies to US, Chi­na biotech Ori­cell rais­es ad­di­tion­al $45M

Shang­hai biotech Ori­cell has raised an ad­di­tion­al $45 mil­lion to bankroll its pre­clin­i­cal and ear­ly-stage can­cer cell ther­a­pies, it an­nounced Tues­day morn­ing.

Fol­low­ing a show­ing at AS­CO last year with a GPRC5D-di­rect­ed CAR-T ther­a­py for mul­ti­ple myelo­ma, Ori­cell raised a $120 mil­lion Se­ries B in Ju­ly. The lat­est raise is an ex­ten­sion of that round, and was led by RTW In­vest­ments and Qatar In­vest­ment Au­thor­i­ty, fol­lowed by ex­ist­ing in­vestors Qim­ing Ven­ture Part­ners and C&D Emerg­ing In­dus­try Eq­ui­ty In­vest­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER